Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q4 2019 · 10-K
Revenue$360.40M$360.40M+33.1% vs Q4 2018 Net Income$46.90M$46.90MN/M vs Q4 2018 EPS Diluted$0.90$0.90N/M vs Q4 2018 Gross Profit$77,800,000+594.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flowderived$122,100,000N/M Free Cash Flowderived$86,000,000N/M Margins · derivedGross margin21.6%+17.4 pt vs Q4 2018
Operating margin21.6%+17.4 pt vs Q4 2018
Net margin13.0%+14.3 pt vs Q4 2018
ended Dec 31, 2019 · filed Feb 25, 2020 · 56 d after period end